Access to comprehensive biomarker testing is critical for patients facing non-small cell lung cancer (NSCLC). That's why we are proud to partner with LUNGevity Foundation and over 20 biopharma and diagnostic companies, professional societies, and patient advocacy organizations to equip healthcare decision-makers with unified evidence on the value of biomarker testing and precision medicine in NSCLC to improve patient outcomes. This new hub consolidates key resources and the latest research supporting biomarker testing using broad molecular panels to guide clinical decisions for patients with NSCLC: https://lnkd.in/g7im7fta
